PL324091A1 - Compositions and procedure for treating sclerosis multiplex - Google Patents

Compositions and procedure for treating sclerosis multiplex

Info

Publication number
PL324091A1
PL324091A1 PL95324091A PL32409195A PL324091A1 PL 324091 A1 PL324091 A1 PL 324091A1 PL 95324091 A PL95324091 A PL 95324091A PL 32409195 A PL32409195 A PL 32409195A PL 324091 A1 PL324091 A1 PL 324091A1
Authority
PL
Poland
Prior art keywords
compositions
procedure
sclerosis multiplex
treating sclerosis
treating
Prior art date
Application number
PL95324091A
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of PL324091A1 publication Critical patent/PL324091A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL95324091A 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex PL324091A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15

Publications (1)

Publication Number Publication Date
PL324091A1 true PL324091A1 (en) 1998-05-11

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95324091A PL324091A1 (en) 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
CA2247009C (en) 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
CN1308671A (en) * 1998-05-05 2001-08-15 科里克萨公司 Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
DE60327618D1 (en) 2002-03-27 2009-06-25 Aegera Therapeutics Inc ANTISENSE NUCLEOBASIS AND ITS APPLICATIONS AGAINST IAP
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP3348275A3 (en) * 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
EA024832B1 (en) 2009-10-12 2016-10-31 ЛАЙФБИО ЛАБОРАТОРИС ЭлЭлСи Oligopeptide binding anti mbp hydrolyzing auto antibodies, compositions and method of treating multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
EP3094341B1 (en) 2014-01-13 2019-10-02 Berg LLC Enolase 1 (eno1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (en) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド Treatment of autoimmune disease by oral administration of self-antigen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DK0506785T3 (en) * 1989-12-20 2000-07-24 Autoimmune Inc Improved treatment of autoimmune diseases by aerosol administration of autoantigens
EP0782859A1 (en) * 1990-03-02 1997-07-09 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc Peptide capable of stimulating a subgroup of t-cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
EP0661996A4 (en) * 1991-11-19 1997-05-21 Anergen Inc Mhc subunit conjugates useful in ameliorating deleterious immune responses.
BR9306042A (en) * 1992-02-28 1997-11-18 Autoimmune Inc Method to treat an autoimmune disease in a mammal and oral and inhalable pharmaceutical dosage forms
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
DE69320967T2 (en) * 1992-04-09 1999-05-12 Autoimmune Inc SUPPRESSION OF T-CELL PROLIFERATION BY MEANS OF PEPTIDE FRAGMENTS OF THE MYELINE BASIC PROTEIN
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
CA2172512A1 (en) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
AU686797B2 (en) * 1994-04-08 1998-02-12 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
JPH10500109A (en) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン Compositions and methods of treatment for multiple sclerosis
JP3558347B2 (en) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー Alpha B crystallin for use in the diagnosis and treatment of autoimmune diseases, especially multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2205532A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
HUT77047A (en) 1998-03-02
IS4466A (en) 1997-04-17
NO971900D0 (en) 1997-04-24
BR9509438A (en) 1997-12-23
SK51297A3 (en) 1998-03-04
FI971750A0 (en) 1997-04-24
NO971900L (en) 1997-06-25
CZ122697A3 (en) 1997-09-17
JPH10504039A (en) 1998-04-14
WO1996012737A3 (en) 1996-10-10
AU4278296A (en) 1996-05-15
WO1996012737A2 (en) 1996-05-02
FI971750A (en) 1997-06-24
IL115766A0 (en) 1996-01-19
EP0787147A1 (en) 1997-08-06
SI9520118A (en) 1998-08-31
CA2203629A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
PL324091A1 (en) Compositions and procedure for treating sclerosis multiplex
GB9422571D0 (en) Haemorrihoidal compositions and method of use
IL129138A0 (en) Methods and compositions for immunomodulation
IL127446A0 (en) Compositions and methods for coating medical devices
EP0874828A4 (en) Composition for treating pain
GB9415421D0 (en) Cosmetic compositions and processes for manufacture thereof
EP0703282A3 (en) Composition for surface treatment
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
ZA9510792B (en) Polymerization compounds and compositions
GB9624501D0 (en) Insecticial compositions and method
IL111554A0 (en) Methods and compositions for hair treatment
GB9405229D0 (en) Compositions of matter
GB9415420D0 (en) Cosmetic compositions and processes for manufacture thereof
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
EP0835092A4 (en) Composition and treatment for baldness
HU9701150D0 (en) Composition for preventing and treating disturbances of vision
IL124419A0 (en) Composition for treating pain
GB9508546D0 (en) Method and composition
PL314588A1 (en) Application of pentoxyphyline in treatment of sclerosis multiplex
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
IL113444A0 (en) Compositions and methods for treating leukemia
GB9416340D0 (en) Oil treatment and compositions therefor
ZA953730B (en) Compositions and treatment for multiple sclerosis
ZA959033B (en) Composition and treatment for multiple sclerosis